Skip to main content
. Author manuscript; available in PMC: 2010 Sep 15.
Published in final edited form as: Clin Cancer Res. 2009 Sep 1;15(18):5910–5916. doi: 10.1158/1078-0432.CCR-09-0542

Table 1. Patient demographics and baseline disease characteristics.

Characteristics N=53 (%)
Age, years
 Mean±SD 55±12
 Range 24-83

Male gender, n (%) 31 (59)

WHO performance status, n (%)
 Grade 0 29 (55)
 Grade 1 23 (43)
 Grade 2 1 (2)

Primary site of cancer, n (%)
 Small intestine 21 (40)
 Stomach 12 (23)
 Colon 3 (6)
 Other* 17 (32)

Time on imatinib, n (%)
<6 months 2 (4)
≥6-<12 months 3 (6)
≥12-<24 months 6 (11)
≥24 months 42 (79)

Other prior tyrosine kinase inhibitor treatment, n (%)
Sunitinib 33 (62)
AMG706, RAD001, dasatinib, or VEG10003 12 (23)
*

Includes colon, peritoneum, rectum and other abdominal sites

SD=Standard deviation; WHO=World Health Organization